Zusammenfassung
Der systemische Lupus erythematodes (SLE) ist die klassische systemische Autoimmunerkrankung. Die Prävalenz liegt in Europa bei Frauen etwas unter 1:1000, bei Männern eine Zehnerpotenz niedriger. Typischerweise tritt die Erkrankung bei Patientinnen im gebärfähigen Alter auf. Während der schwere SLE unbehandelt eine regelhaft tödliche Erkrankung war, hat sich die Prognose schrittweise durch Glukokortikoide, Immunsuppressiva und schließlich innovative Behandlungsverfahren dramatisch verbessert. Direkt durch den SLE verursachte Todesfälle sind heute selten, wenn auch Infektionen, Thrombosen und beschleunigte Arteriosklerose signifikante Probleme darstellen. Diese Übersichtsarbeit hat das Ziel, den heutigen Stand des Managements von Lupuspatienten darzustellen.
Abstract
Systemic lupus erythematosus (SLE) is the classical systemic autoimmune disease. Its prevalence is slightly below 1:1,000 in women and 10-fold lower in men. Typically, the disease manifests in women of childbearing age. While severe untreated SLE used to be a fatal disease, prognosis has improved stepwise with corticosteroids, cyclophosphamide and novel therapies. Deaths directly related to SLE are uncommon nowadays but infections, thromboses and accelerated atherosclerosis cause significant problems. The current review presents the state of the art in managing SLE patients.
Literatur
Alexander T, Thiel A, Rosen O et al (2009) Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 113:214–223
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
Bertsias G, Ioannidis JP, Boletis J et al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67:195–205
Petri M, Kim MY, Kalunian KC et al (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353:2550–2558
Mosca M, Tani C, Aringer M et al (2010) European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 69:1269–1274
Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69:20–28
Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306
Bertsias GK, Ioannidis JP, Aringer M et al (2010) EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 69:2074–2082
Weening JJ, D’Agati VD, Schwartz MM et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65:521–530
Houssiau FA, Vasconcelos C, D’Cruz D et al (2010) The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69:61–64
Appel GB, Contreras G, Dooley MA et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103–1112
Winzer M, Aringer M (2010) Use of methotrexate in patients with systemic lupus erythematosus and primary Sjogren’s syndrome. Clin Exp Rheumatol 28(5 Suppl 61):S156–S159
Galie N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493–2537
Kuhn A, Ochsendorf F, Bonsmann G (2010) Treatment of cutaneous lupus erythematosus. Lupus 19:1125–1136
Navarra SV, Guzman RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377(9767):721–731
Jonsdottir T, Gunnarsson I, Mourao AF et al (2010) Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology (Oxford) 49:1502–1504
Stummvoll GH, Julius U, Derfler K, Aringer M (2009) Immunoadsorption for systemic lupus erythematosus. Atheroscler Suppl 10:110–113
Interessenkonflikt
Der korrespondierende Autor weist auf folgende Beziehungen hin: Roche, GSK (Advisory Boards), Centocor (Grant).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aringer, M., Hiepe, F. Systemischer Lupus erythematodes. Z. Rheumatol. 70, 313–323 (2011). https://doi.org/10.1007/s00393-011-0794-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-011-0794-6